For the Inventor, By the Inventor

Enter inventor name

Newtown, PA, United States of America

William John Pitts

USPTO Granted Patents = 53 (Patent Applications = 2)

EPO Patents = 18 (Patent Applications = 15)

Average Co-Inventor Count = 5.2

ph-index = 13

Forward Citations = 617(Granted Patents)

Forward Citations (Not Self Cited) = 597(Dec 10, 2025)

Location History:

Conshohocken, PA (US) (1995 - 2000)
Newark, DE (US) (1997 - 2001)
Newtown, PA (US) (2002 - 2024)

Company Filing History:

43 out of 3,684

Bristol-myers Squibb Compnay

The Dupont Merck Pharmaceutical Company

Dupont Pharmaceuticals Company

4. 1 out of 234

Bristol-myers Squibb Pharma Company

Bristol Meyers Squibb Company

Dupont Pharmaceuticals, Inc.

Years Active: 1995-2025

Loading Chart...

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Heterocyclic Compounds

Inflammatory Diseases

Autoimmune Diseases

Integrin Antagonists

Phosphodiesterase Inhibitors

Tricyclic Compounds

Aminopyrrolotriazines

Indazole Carboxamides

JAK3 Inhibitors

Barbituric Acid Derivatives

Fused Heterocyclic Compounds

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275721 - Indazole carboxamides as kinase inhibitors (2025-04-14),

2. 12240840 - Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha (2025-03-04),

3. 12172975 - 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) (2024-12-24),

4. 12157733 - Aminotriazolopyridines as kinase inhibitors (2024-12-03),

5. 12084426 - Indazole carboxamides as kinase inhibitors (2024-09-10),

6. 11618753 - Aminopyrrolotriazines as kinase inhibitors (2023-04-04),

7. 11440913 - Aminoimidazopyridazines as kinase inhibitors (2022-09-13),

8. 10913738 - Aminotriazolopyridines as kinase inhibitors (2021-02-09),

9. 10865191 - Heterocyclic compounds useful as modulators of TNF alpha (2020-12-15),

10. 10544133 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2020-01-28),

11. 10301306 - Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors (2019-05-28),

12. 10227340 - Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors (2019-03-12),

13. 10023562 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2018-07-17),

14. 9862715 - Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors (2018-01-09),

15. 9657009 - Heteroaryl substituted pyridyl compounds useful as kinase modulators (2017-05-23),

Title: The Innovative Contributions of William John Pitts

Introduction: William John Pitts, a prominent inventor based in Newtown, PA, has made significant contributions to the field of pharmacology through his 51 patents. His work primarily focuses on developing compounds that act as inhibitors for various kinases, showcasing his deep understanding of molecular interactions and therapeutic applications.

Latest Patents: Among his most recent patents are developments related to 1H-indazole carboxamides and aminotriazolopyridines. The first patent describes 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1), highlighting compounds that can modulate kinase activity, including RIPK1 modulation. Similarly, his innovations in aminotriazolopyridines involve the development of compounds that serve as kinase modulators, underscoring their role in molecular biology and drug design.

Career Highlights: Throughout his career, William John Pitts has collaborated with leading pharmaceutical companies such as Bristol-Myers Squibb Company and The DuPont Merck Pharmaceutical Company. His extensive experience in these esteemed firms has allowed him to develop a robust portfolio of patents that contribute to advancements in medicinal chemistry.

Collaborations: In his professional journey, Pitts has worked alongside notable colleagues, including Junqing Guo and Steven H. Spergel. These collaborations have fostered an environment of innovation and scientific inquiry, enabling the exploration of groundbreaking ideas and technologies in drug development.

Conclusion: William John Pitts is a distinguished figure in the realm of inventions and patents, with his innovative contributions continuing to influence the landscape of pharmaceutical research. His dedication to creating effective kinase inhibitors showcases the vital role of inventors in advancing healthcare and improving therapeutic outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…